Literature DB >> 1734291

Prevalence of dementia and probable senile dementia of the Alzheimer type in the Framingham Study.

D L Bachman1, P A Wolf, R Linn, J E Knoefel, J Cobb, A Belanger, R B D'Agostino, L R White.   

Abstract

We determined the prevalence of dementia and probable senile dementia of the Alzheimer type (SDAT) for biennial Exam 17 of the Framingham cohort (1982/1983). The prevalence of dementia was 30.5/1,000 for men and 48.2/1,000 for women and increased with advancing age. Cases of probable SDAT constituted 55.6% of all dementia cases. THe prevalence of SDAT was 11.7/1,000 for men and 30.1/1,000 for women and also increased with advancing age. Prevalence of dementia and probable SDAT were greater for women than men. The female:male ratio of prevalence for cohort members 75 years of age and older was 1.8 for all cases of dementia and 2.8 for cases of probable SDAT.

Entities:  

Mesh:

Year:  1992        PMID: 1734291     DOI: 10.1212/wnl.42.1.115

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  112 in total

Review 1.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

2.  Tacrine for Alzheimer's disease. Costs and benefits.

Authors:  D Knopman
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

3.  White matter hyperintensity and cognitive functioning in the racial and ethnic minority cohort of the Framingham Heart Study.

Authors:  Karina Stavitsky; Yangchun Du; Daniel Seichepine; Thomas M Laudate; Alexa Beiser; Sudha Seshadri; Charles Decarli; Philip A Wolf; Rhoda Au
Journal:  Neuroepidemiology       Date:  2010-06-15       Impact factor: 3.282

4.  The PREMAP Study: prevalence and risk factors of dementia and clinically diagnosed Alzheimer's disease in Provence, France. Prevalence of Alzheimer's Disease in Provence.

Authors:  Y Obadia; M Rotily; A Degrand-Guillaud; J Guelain; M Ceccaldi; C Severo; M Poncet; A Alperovitch
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

5.  The 5XFAD Mouse Model of Alzheimer's Disease Exhibits an Age-Dependent Increase in Anti-Ceramide IgG and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden.

Authors:  Michael B Dinkins; Somsankar Dasgupta; Guanghu Wang; Gu Zhu; Qian He; Ji Na Kong; Erhard Bieberich
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

6.  Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.

Authors:  Marybeth Camboni; Chiou-Miin Wang; Carlos Miranda; Jung Hae Yoon; Rui Xu; Deborah Zygmunt; Brian K Kaspar; Paul T Martin
Journal:  Neurobiol Dis       Date:  2013-09-08       Impact factor: 5.996

Review 7.  Sex differences in cognitive impairment and Alzheimer's disease.

Authors:  Rena Li; Meharvan Singh
Journal:  Front Neuroendocrinol       Date:  2014-01-13       Impact factor: 8.606

Review 8.  The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia.

Authors:  X Du; R A Hill
Journal:  J Mol Neurosci       Date:  2016-08-15       Impact factor: 3.444

Review 9.  Genomic variants, genes, and pathways of Alzheimer's disease: An overview.

Authors:  Adam C Naj; Gerard D Schellenberg
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

10.  Gender-specificities in Alzheimer's disease and mild cognitive impairment.

Authors:  U Beinhoff; H Tumani; J Brettschneider; D Bittner; M W Riepe
Journal:  J Neurol       Date:  2008-01-18       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.